Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.
about
Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Drivers of Iclaprim.Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres.Defeating Antibiotic- and Phage-Resistant Enterococcus faecalis Using a Phage Cocktail in Vitro and in a Clot Model.
P2860
Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy of iclaprim against w ...... an in vitro fibrin clot model.
@en
Efficacy of iclaprim against w ...... an in vitro fibrin clot model.
@nl
type
label
Efficacy of iclaprim against w ...... an in vitro fibrin clot model.
@en
Efficacy of iclaprim against w ...... an in vitro fibrin clot model.
@nl
prefLabel
Efficacy of iclaprim against w ...... an in vitro fibrin clot model.
@en
Efficacy of iclaprim against w ...... an in vitro fibrin clot model.
@nl
P2093
P2860
P356
P1476
Efficacy of iclaprim against w ...... an in vitro fibrin clot model.
@en
P2093
Andreas Haldimann
José M Entenza
Marlyse Giddey
Philippe Moreillon
Sergio Lociuro
Stephen Hawser
P2860
P304
P356
10.1128/AAC.00325-09
P407
P577
2009-06-29T00:00:00Z